201 related articles for article (PubMed ID: 19259093)
1. Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival.
Kim JS; Kim MA; Kim TM; Lee SH; Kim DW; Im SA; Kim TY; Kim WH; Yang HK; Heo DS; Bang YJ; Lee KU; Choe KJ; Kim NK
Br J Cancer; 2009 Mar; 100(5):732-8. PubMed ID: 19259093
[TBL] [Abstract][Full Text] [Related]
2. Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
Hwang JE; Kim H; Shim HJ; Bae WK; Hwang EC; Jeong O; Ryu SY; Park YK; Cho SH; Chung IJ
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2157-2166. PubMed ID: 31273512
[TBL] [Abstract][Full Text] [Related]
3. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.
Matsubara J; Nishina T; Yamada Y; Moriwaki T; Shimoda T; Kajiwara T; Nakajima TE; Kato K; Hamaguchi T; Shimada Y; Okayama Y; Oka T; Shirao K
Br J Cancer; 2008 Feb; 98(4):832-9. PubMed ID: 18231104
[TBL] [Abstract][Full Text] [Related]
4. A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer.
Lee SS; Jeung HC; Chung HC; Noh SH; Hyung WJ; Ahn JY; Rha SY
Invest New Drugs; 2012 Feb; 30(1):357-63. PubMed ID: 20734110
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer.
Sonnenblick A; Rottenberg Y; Kadouri L; Wygoda M; Rivkind A; Vainer GW; Peretz T; Hubert A
Med Oncol; 2012 Dec; 29(5):3035-8. PubMed ID: 22773040
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
Soong R; Shah N; Salto-Tellez M; Tai BC; Soo RA; Han HC; Ng SS; Tan WL; Zeps N; Joseph D; Diasio RB; Iacopetta B
Ann Oncol; 2008 May; 19(5):915-9. PubMed ID: 18245778
[TBL] [Abstract][Full Text] [Related]
7. Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
Choi JH; Lim HY; Joo HJ; Kim HS; Yi JW; Kim HC; Cho YK; Kim MW; Lee KB
Br J Cancer; 2002 May; 86(10):1578-85. PubMed ID: 12085207
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy.
Kang BW; Jeong JY; Chae YS; Lee SJ; Lee YJ; Choi JY; Lee IK; Jeon SW; Bae HI; Lee DK; Kwon OK; Chung HY; Yu W; Kim JG
Cancer Chemother Pharmacol; 2012 Nov; 70(5):735-41. PubMed ID: 22955258
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
10. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Terashima M; Fujiwara H; Takagane A; Abe K; Irinoda T; Nakaya T; Yonezawa H; Oyama K; Saito K; Kanzaki N; Ohtani S; Nemoto T; Hoshino Y; Kogure M; Gotoh M
Gastric Cancer; 2003; 6 Suppl 1():71-81. PubMed ID: 12775024
[TBL] [Abstract][Full Text] [Related]
11. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of the concomitant existence of lymphovascular and perineural invasion in locally advanced gastric cancer patients who underwent curative gastrectomy and adjuvant chemotherapy.
Hwang JE; Hong JY; Kim JE; Shim HJ; Bae WK; Hwang EC; Jeong O; Park YK; Lee KH; Lee JH; Cho SH; Chung IJ
Jpn J Clin Oncol; 2015 Jun; 45(6):541-6. PubMed ID: 25759484
[TBL] [Abstract][Full Text] [Related]
13. Increasing nodal ratio is a poor prognostic factor for survival in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study.
Kim JS; Kim MA; Oh DY; Lee SH; Kim DW; Im SA; Kim WH; Yang HK; Heo DS; Bang YJ; Lee KU; Kim TY; Kim TM; Kim NK; Choe KJ
Jpn J Clin Oncol; 2011 Feb; 41(2):245-52. PubMed ID: 21106599
[TBL] [Abstract][Full Text] [Related]
14. Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy.
Lee J; Park CK; Park JO; Lim T; Park YS; Lim HY; Lee I; Sohn TS; Noh JH; Heo JS; Kim S; Lim DH; Kim KM; Kang WK
Clin Cancer Res; 2008 Jan; 14(1):82-8. PubMed ID: 18172256
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
[TBL] [Abstract][Full Text] [Related]
16. ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy.
De Dosso S; Zanellato E; Nucifora M; Boldorini R; Sonzogni A; Biffi R; Fazio N; Bucci E; Beretta O; Crippa S; Saletti P; Frattini M
Cancer Chemother Pharmacol; 2013 Jul; 72(1):159-65. PubMed ID: 23645290
[TBL] [Abstract][Full Text] [Related]
17. Postoperative chemotherapy followed by conformal concomitant chemoradiotherapy in high-risk gastric cancer.
Quero L; Bouchbika Z; Kouto H; Baruch-Hennequin V; Gornet JM; Munoz N; Cojean-Zelek I; Houdart R; Panis Y; Valleur P; Aparicio T; Maylin C; Hennequin C
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):574-80. PubMed ID: 22099038
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
[TBL] [Abstract][Full Text] [Related]
19. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
Kwon HC; Roh MS; Oh SY; Kim SH; Kim MC; Kim JS; Kim HJ
Ann Oncol; 2007 Mar; 18(3):504-9. PubMed ID: 17322540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]